Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus

Abbasi, Fahim; Chu, James W.; McLaughlin, Tracey; Lamendola, Cindy; Leary, Eileen; Reaven, Gerald M.

doi:10.1016/j.metabol.2003.07.020

Cited by 148 publications

(108 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…a major precursor in the formation of AGE) and albuminuria (19,37,(45)(46)(47)(48) and either decrease (20,22,37,(49)(50)(51) or having no significant effect (19,20,24,37,50) on circulating levels of CRP, TNF-a, PAI-1-ag, t-PA-ag, sICAM-1 and sE-selectin. For albuminuria, also an increase has been observed after metformin therapy (37).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes

Lund

Tarnow

Stehouwer

et al. 2008

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: In patients with type 2 diabetes mellitus (T2DM), biomarkers reflecting inflammation and endothelial dysfunction have been linked to cardiovascular disease (CVD biomarkers) and metabolic regulation. In T2DM patients, metformin and insulin secretagogues have demonstrated equal antihyperglycaemic potency. Here, we report the effect of metformin versus an insulin secretagogue, repaglinide, on CVD biomarkers in non-obese T2DM patients. Design and methods: Single-centre, double-masked, double-dummy, crossover study during 2!4 months involving 96 non-obese (body mass index%27 kg/m 2 ) insulin-naïve T2DM patients. At enrolment, previous oral hypoglycaemic agents were stopped and the patients entered a 1-month runin on diet-only treatment. Hereafter, patients were randomized to either 2 mg repaglinide thrice daily followed by 1 g metformin twice daily or vice versa each during 4 months with a 1-month washout between interventions. Results: Levels of tumour necrosis factor-a, plasminogen activator inhibitor-1 antigen, tissue-type plasminogen activator antigen, von Willebrand factor, soluble intercellular adhesion molecule-1 and soluble E-selectin were significantly lower during metformin versus repaglinide treatments. In contrast, Amadori albumin and heart rate were higher during metformin versus repaglinide. Levels of interleukin-6, fibrinogen, soluble vascular cell adhesion molecule-1, asymmetric dimethylarginine and advanced glycation end products as well as glycaemic levels (previously reported) and 24-h blood pressure were similar between treatments. Adjustment for known macrovascular disease did not affect the between-treatment effects. Conclusions: In non-obese T2DM patients, metformin was more effective in reducing selected biomarkers reflecting inflammation and endothelial dysfunction compared with repaglinide despite similar glycaemic levels between treatments.European Journal of Endocrinology 158 631-641

show abstract

Section: Discussionmentioning

confidence: 99%

“…Thus, biological mechanisms both dependent and independent of glycaemia might influence the CVD biomarkers. As yet, few studies have compared the effect of various anti-hyperglycaemic treatment regimens on CVD biomarkers, and most studies were in obese patients with T2DM (17,(19)(20)(21)(22)(23)(24)(25)(26)(27).…”

Section: Introductionmentioning

confidence: 99%

Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes

Lund

Tarnow

Stehouwer

et al. 2008

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Whereas an earlier study was not able to show any benefit of metformin on LDL particle size in patients suffering from type 2 diabetes (either as monotherapy or in addition to sulfonylurea) [87], recent data from a trial investigating metformin in addition to sulfonylurea suggests an increase in LDL particle size due to an increase in lipoprotein lipase production [88].…”

Section: Antihyperglycemic Treatments With Effects On Ldl Particle DImentioning

confidence: 98%

Small dense low-density lipoprotein particles: priority as a treatment target in Type 2 diabetes?

Gerber¹,

Spinas²,

Berneis³

2012

Diabetes Management

View full text Add to dashboard Cite

During the past two decades, the importance of the quality of low-density lipoprotein (LDL) particles -in addition to its quantity -has become of increasing interest. The risk of cardiovascular events was recognized to be closely linked to a predominance of small, dense LDL particles. In addition, in patients with Type 2 diabetes mellitus, the disease itself and its severity (in particular the degree of insulin resistance) is associated with this subclass of LDL particles. Lipid lowering as well as antihyperglycemic drugs have been evaluated in many studies concerning their effect on LDL particle size. It has increasingly been recognized that a reduction of LDL quantity is not necessarily associated with a beneficial effect on LDL quality. Advances in the understanding of alterations in LDL quality may therefore influence the choice of the therapeutic regimen in patients with diabetes in the future. SummaryDuring the last two decades, the importance of the quality of low-density lipoprotein (LDL) particles -in addition to its quantity -has become of increasing interest. The risk of cardiovascular events was recognized to be closely linked to a predominance of small, dense LDL particles. In addition, in patients with type 2 diabetes mellitus, the disease itself and its severity (in particular the degree of insulin resistance) is associated with this subclass of LDL particles. Lipid lowering as well as antihyperglycemic drugs have been evaluated in many studies concerning their effect on LDL particle size. It has increasingly been recognized that a reduction of LDL quantity is not necessarily associated with a beneficial effect on LDL quality. Advances in the understanding of alterations in LDL quality may therefore influence the choice of the therapeutic regimen in patients with diabetes in the future.

show abstract

“…Metformin has a pluripotent effect, is not metabolized in vivo and has a 50 % bioavailability [14]. A particularly beneficial therapeutic effect of metformin is described in obese patients with T2D [29], cardiovascular complications [1,24], and atherosclerosis [38]. It also has a prophylactic effect, preventing the transition of insulin resistance (IR) to clinically diagnosed T2D [25].…”

Section: Introductionmentioning

confidence: 99%

Роль Імунної Системи У Механізмі Терапевтичної Дії Метформіну У Хворих На Цукровий Діабет 2-Го Типу

Zak¹,

Orlenko²,

Popova³

et al. 2021

Mìžnarodnij endokrinologìčnij žurnal

View full text Add to dashboard Cite

show abstract

Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus

Cited by 148 publications

References 29 publications

Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes

Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes

Small dense low-density lipoprotein particles: priority as a treatment target in Type 2 diabetes?

Роль Імунної Системи У Механізмі Терапевтичної Дії Метформіну У Хворих На Цукровий Діабет 2-Го Типу

Contact Info

Product

Resources

About